Veracyte (VCYT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.88 (+2.05%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Veracyte (VCYT)
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.

Key Insights

Critical company metrics and information
  • Share Price

    $43.58
  • Market Cap

    $3.38 Billion
  • Total Outstanding Shares

    77.50 Million Shares
  • Total Employees

    815
  • Dividend

    No dividend
  • IPO Date

    October 30, 2013
  • SIC Description

    Services-medical Laboratories
  • Homepage

    https://www.veracyte.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$10.06 Million
Net Cash Flow, Continuing$71.55 Million
Net Cash Flow From Investing Activities, Continuing$-4.63 Million
Net Cash Flow From Operating Activities$66.12 Million
Net Cash Flow$71.83 Million
Net Cash Flow From Operating Activities, Continuing$66.12 Million
Net Cash Flow From Financing Activities, Continuing$10.06 Million
Net Cash Flow From Investing Activities$-4.63 Million
Exchange Gains/Losses$274,000.00

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$-8.17 Million
Net Income/Loss Available To Common Stockholders, Basic$-9.27 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Diluted Earnings Per Share$-0.13
Basic Earnings Per Share$-0.13
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Other Operating Expenses$370.41 Million
Income Tax Expense/Benefit$1.10 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Parent$-9.27 Million
Costs And Expenses$439.09 Million
Operating Expenses$439.09 Million
Operating Income/Loss$-23.54 Million
Revenues$425.33 Million
Benefits Costs and Expenses$433.50 Million
Net Income/Loss$-9.27 Million
Basic Average Shares$76.26 Million
Research and Development$68.68 Million
Income/Loss From Continuing Operations After Tax$-9.27 Million
Diluted Average Shares$77.50 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$28.67 Million
Other Non-current Assets$809.29 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity$1.18 Billion
Current Liabilities$70.31 Million
Accounts Payable$9.67 Million
Liabilities$98.98 Million
Intangible Assets$108.87 Million
Assets$1.28 Billion
Equity Attributable To Parent$1.18 Billion
Noncurrent Assets$918.17 Million
Liabilities And Equity$1.28 Billion
Other Current Assets$336.49 Million
Inventory$20.36 Million
Current Assets$356.85 Million
Wages$30.74 Million
Other Current Liabilities$29.90 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Veracyte (VCYT)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.